AI-Powered Real-World Evidence (RWE) Solutions Market Current Scenario with Future Aspect Analysis

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “AI-Powered Real-Worl Evidence (RWE) Solutions Market”-, By Component(Software/Platforms, Services), By Data Source(EHR/EMR Data, Claims Data, Genomics, Wearables/IoT, Patient-Reported Data, Imaging), By Therapeutic Area(Oncology, Neurology, Cardiology, Rare Diseases, Immunology), By End-User (Pharma/Biotech, Payers/PBMs, Hospitals/IDNs, Regulators, CROs), By Deployment Model (Cloud-Based, On-Premise, Hybrid), By Technology (NLP, Computer Vision, Federated Learning, Graph ML), By Application (Drug Development, Regulatory Submissions, Market Access, Precision Medicine), and Global Forecasts, 2025-2034 And Segment Revenue and Forecast To 2034.” 

Global AI-Powered Real-World Evidence (RWE) Solutions Market Size is predicted to reach grow at a 14.6 % CAGR during the forecast period for 2025-2034.

 

Get A Free Report Brochure: https://www.insightaceanalytic.com/request-sample/3135 

 

The base of Real-World Evidence (RWE) is Real-World Data (RWD), which comprises information gathered from sources other than controlled clinical trials, such as wearable technology, medical claims, registries, electronic health records (EHRs), and patient-generated data.  By offering actionable insights from intricate, varied datasets, these technologies seek to improve patient outcomes, expedite drug discovery, and improve healthcare decision-making.  Based on the material at hand, the following provides a thorough overview of AI-powered RWE solutions. AI-powered, More and more sophisticated and successful pharmaceutical clinical trials are being developed using real-world evidence.  Real-world patient data helps trial designers comprehend treatment trends, disease progression, and population heterogeneity in ways that RCTs cannot.AI technologies are now being used by pharmaceutical teams to refine inclusion/exclusion criteria, model trial scenarios, and identify high-yield patient populations.  Quicker recruiting, fewer protocol changes, and reduced trial expenditures are made possible by this. In one project, a multinational pharmaceutical corporation optimized trial design using companies.

There has been a tremendous advancement in recent years in the definition of how RWE can be included in regulatory filings.   The FDA’s framework for RWE utilization reflects a higher reliance on real-world data to expedite post-marketing surveillance, label extensions, and therapeutic approvals, while the European Medicines Agency (EMA) promotes adaptive approaches. These frameworks recognize that controlled trial settings may not always accurately reflect how well medications operate in the complex environment of routine clinical practice.  RWE is difficult to use in a regulatory setting, though.   Data must adhere to strict quality requirements.   It needs to be statistically sound, traceable, and reproducible.   Many pharmaceutical teams still view RWE as an ancillary resource rather than a crucial strategic asset. 

 

List of Prominent Players in the AI-Powered Real-World Evidence (RWE) Solutions Market:

  • Aetion
  • Atropos Health
  • ConcertAI
  • Envision Pharma Group
  • Flatiron Health
  • Health Compiler
  • Huma
  • IQVIA
  • ai
  • Komodo Health
  • NVIDIA CLARA
  • OM1
  • ai
  • Optum
  • Owkin
  • Panalgo
  • Realyze Intelligence
  • Syntropy
  • Tempus
  • AI
  • Veradigm
  • Other Prominent Players

 

Market Dynamics:

Drivers:

Healthcare is moving toward a more quality-oriented future where the focus is on the caliber of services rendered. Many hospitals are aware of the shortcomings of conventional methods in terms of cost-effectiveness and patient care. As a result, healthcare is changing from volume to value-based care, which emphasizes data that is focused on outcomes. Using healthcare innovations to improve quality of life is known as value-based care, according to the American Journal of Managed Care. Sets of common parameters used to evaluate the cost-effectiveness and value of these interventions are used to identify them. As a result, the majority of hospitals are moving toward value-based care as they realize how unproductive traditional methods to patient care are.

 

Order this Premium Report: https://www.insightaceanalytic.com/select-license/ai-powered-real-world-evidence-rwe-solutions-market/3135

 

Challenges:

The market for real-world evidence solutions is growing slowly because there aren’t enough qualified workers to manage sophisticated digital systems. In the clinical research sector, there is a shortage of skilled workers compared to the demand, which hinders the use of sophisticated and challenging software in clinical trials.

Regional Trends: 

North America has the largest market share during the forecast period. The growing number of payers utilizing Real World Data (RWD), a supportive regulatory environment, an increase in RWE service providers, and a growing number of pharmaceutical companies implementing RWE solutions for drug approval procedures are all factors propelling the real-world evidence solutions market in the United States. The substantial market share in this area is driven by a number of variables, such as the growing number of chronic illnesses, stricter medication approval laws, the accessibility of electronic datasets, improvements in the healthcare sector, and the expanding amount of big data in healthcare. 

Recent Developments:

  • In Jan 2025, Atropos Health and xCures declared a collaboration to use RWE-based analytics to improve patient care. Through this collaboration, the businesses will use AI, the xCures Platform, and the Atropos EvidenceTM Network to create and distribute highly proven prognostic and decision support tools to healthcare providers throughout the healthcare ecosystem. 
  • In July 2021, Syneos Health and Aetion declared a collaboration to offer analytics-driven solutions and regulatory-grade data to enhance medication development and improve patient outcomes. The collaboration combines Aetion Evidence Platform (AEP) with Syneos Health’s in-house data collecting and research tools to produce evidence through real-world evidence (RWE) analytics and patient data curation.  Biopharmaceutical companies can reduce risk through evidence-based decision-making, speed up product development and patient access to new therapies, and prove value to a wide range of healthcare stakeholders, including patients, regulators, payers, and healthcare providers, with Syneos Health’s offerings, such as its Biopharmaceutical Acceleration Model, Dynamic Assembly, and RWE Solutions.

Global AI-Powered Real-World Evidence (RWE) Solutions Market – By Component

  • Software/Platforms
  • Services

Global AI-Powered Real-World Evidence (RWE) Solutions Market – By Data Source

  • EHR/EMR Data
  • Claims Data
  • Genomics
  • Wearables/IoT
  • Patient-Reported Data
  • Imaging

Global AI-Powered Real-World Evidence (RWE) Solutions Market – By Therapeutic Area

  • Oncology
  • Neurology
  • Cardiology
  • Rare Diseases
  • Immunology

Global AI-Powered Real-World Evidence (RWE) Solutions Market – By End-User

  • Pharma/Biotech
  • Payers/PBMs
  • Hospitals/IDNs
  • Regulators
  • CROs

Global AI-Powered Real-World Evidence (RWE) Solutions Market – By Deployment Model

  • Cloud-Based
  • On-Premise
  • Hybrid

Global AI-Powered Real-World Evidence (RWE) Solutions Market – By Technology

  • NLP
  • Computer Vision
  • Federated Learning
  • Graph ML

Global AI-Powered Real-World Evidence (RWE) Solutions Market – By Application

  • Drug Development
  • Regulatory Submissions
  • Market Access
  • Precision Medicine

Global AI-Powered Real-World Evidence (RWE) Solutions Market – By Region

North America-

  • The US
  • Canada

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of the Middle East and Africa

 

Details insights on this market: https://www.insightaceanalytic.com/report/ai-powered-real-world-evidence-rwe-solutions-market/3135

 

About Us:

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

 

Contact US:

InsightAce Analytic Pvt. Ltd.

Tel.: +1 718 593 4405

Email: info@insightaceanalytic.com

Site Visit: www.insightaceanalytic.com

Follow Us on LinkedIn @ bit.ly/2tBXsgS

Follow Us On Facebook @ bit.ly/2H9jnDZ

    Written by

    Insightace Analytic

    InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and re positioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

    Leave a Comment